SCH 503034, a Novel Hepatitis C Virus Protease Inhibitor, Plus Pegylated Interferon α-2b for Genotype 1 Nonresponders
Top Cited Papers
Open Access
- 1 April 2007
- journal article
- research article
- Published by Elsevier in Gastroenterology
- Vol. 132 (4) , 1270-1278
- https://doi.org/10.1053/j.gastro.2007.01.041
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Rapid Decline of Viral RNA in Hepatitis C Patients Treated With VX-950: A Phase Ib, Placebo-Controlled, Randomized StudyGastroenterology, 2006
- A randomised trial to compare the pharmacokinetic, pharmacodynamic, and antiviral effects of peginterferon alfa-2b and peginterferon alfa-2a in patients with chronic hepatitis C (COMPARE)Journal of Hepatology, 2006
- 39 Valopicitabine (NM283), alone or with peginterferon, compared to peg interferon/ribavirin (pegifn/RBV) re-treatment in hepatitis patients with prior non-response to PEGIFN/RBV: Week 24 resultsJournal of Hepatology, 2006
- 737 Initial results of a 14-day study of the hepatitis C virus inhibitor protease VX-950, in combination with peginterferon-alpha-2aJournal of Hepatology, 2006
- 736 Early clearance of HCV RNA with valopicitabine (NM283) plus PEG-Interferon in treatment-naïve patients with HCV-1 infection: First results from a phase IIb trialJournal of Hepatology, 2006
- 731 Interim results of a multiple ascending dose study of R1626, a novel nucleoside analog targeting hcv polymerase in chronic HCV patientsJournal of Hepatology, 2006
- Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremiaJournal of Hepatology, 2005
- Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virusNature, 2005
- Evasion of intracellular host defence by hepatitis C virusNature, 2005
- Antiviral efficacy of NS3‐serine protease inhibitor BILN‐2061 in patients with chronic genotype 2 and 3 hepatitis C†‡Hepatology, 2005